{"id":88810,"date":"2026-06-21T06:36:57","date_gmt":"2026-06-21T06:36:57","guid":{"rendered":"https:\/\/www.europesays.com\/ch\/88810\/"},"modified":"2026-06-21T06:36:57","modified_gmt":"2026-06-21T06:36:57","slug":"roche-sticks-to-german-investment-after-eli-lilly-cuts-2","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/ch\/88810\/","title":{"rendered":"Roche sticks to German investment after Eli Lilly cuts"},"content":{"rendered":"<p>FRANKFURT, June 9 (Reuters) &#8211; The Swiss pharmaceutical and diagnostics giant Roche <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/ROPC.S\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(ROPC.S), opens new tab<\/a> said it is sticking to its \u200bplanned investments in Germany, unlike some of \u200cits competitors that have scaled back spending in the country.<\/p>\n<p>The company will continue its \u20ac600 million ($692.88 million) investment \u200bin a new diagnostic production site in \u200bPenzberg, Germany, Roche told Reuters.<\/p>\n<p data-testid=\"promo-box\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__promo-box__hVl8h\"> Sign up  <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/business\/healthcare-pharmaceuticals\/roche-sticks-german-investment-after-eli-lilly-cuts-2026-06-09\/undefined?location=article-paragraph&amp;redirectUrl=%2Fbusiness%2Fhealthcare-pharmaceuticals%2Froche-sticks-german-investment-after-eli-lilly-cuts-2026-06-09%2F\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">here.<\/a><\/p>\n<p>This comes after \u2060U.S.-based Eli Lilly <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/markets\/companies\/LLY.N\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">(LLY.N), opens new tab<\/a> said it would <a data-testid=\"Link\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.reuters.com\/business\/lilly-halve-planned-23-billion-investment-germany-ceo-tells-newspaper-2026-06-03\/\" class=\"text-module__text__0GDob text-module__inherit-color__PhuPF text-module__inherit-font__1P1hv text-module__inherit-size__EyiQW link-module__link__INqxZ link-module__underline_default__-okuC\" rel=\"nofollow noopener\" target=\"_blank\">halve its $2.3 billion \u200binvestment<\/a> in Germany and German drugmaker Boehringer Ingelheim scrapped \u200bits \u20ac900 million plans, both citing the government&#8217;s planned healthcare cost-cutting measures.<\/p>\n<p>Roche said it would also now have to \u200breview its future investments in Germany carefully.<\/p>\n<p>The \u200bdecision for Roche&#8217;s investment in Penzberg, its largest single one \u200cin \u2060Germany, was made several years ago, with construction expected to be completed by 2027.<\/p>\n<p>&#8220;The cabinet decision is creating a new degree of uncertainty \u200bregarding investments, research, \u200band \u2060production decisions in Germany,&#8221; Daniel Steiners, CEO of Roche Pharma AG, told \u200bReuters.<\/p>\n<p>He added that the government risked \u200bcausing significant \u2060economic damage with minimal benefit for a sustainable healthcare system, and said the parliamentary process now \u2060offered \u200ba final chance to \u200bkeep Germany on a reliable path.<\/p>\n<p>($1 = 0.8660 euros)<\/p>\n<p data-testid=\"SignOff\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__extra_small__8Buss body-module__full_width__kCIGb body-module__extra_small_body__Bfz20 sign-off-module__text__LQAMP\">Reporting by Patricia Weiss, \u200bwriting by Marleen Kaesebier, editing by Linda Pasquini<\/p>\n<p data-testid=\"Body\" dir=\"ltr\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__regular__qJJtA text-module__small__sph8i body-module__base__o--Cl body-module__small_body__gOmDf article-body-module__element__5eCce article-body-module__trust-badge__5mS3f\">Our Standards: <a data-testid=\"Link\" target=\"_blank\" referrerpolicy=\"no-referrer-when-downgrade\" href=\"https:\/\/www.thomsonreuters.com\/en\/about-us\/trust-principles.html\" rel=\"noopener nofollow\" class=\"text-module__text__0GDob text-module__dark-grey__UFC18 text-module__medium__2Rl30 text-module__small__sph8i link-module__link__INqxZ link-module__underline_default__-okuC link-module__with-icon__qlg76\">The Thomson Reuters Trust Principles., opens new tab<\/a><\/p>\n<p><a href=\"https:\/\/www.reutersagency.com\/en\/licensereuterscontent\/?utm_medium=rcom-article-media&amp;utm_campaign=rcom-rcp-lead\" target=\"_blank\" dir=\"ltr\" class=\"button-module__link__A3sD0 button-module__secondary__70gBu button-module__round__QDFgq button-module__w_auto__Sem-F\" data-testid=\"LicenceContentButton\" rel=\"nofollow noopener\">Purchase Licensing Rights<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"FRANKFURT, June 9 (Reuters) &#8211; The Swiss pharmaceutical and diagnostics giant Roche (ROPC.S), opens new tab said it&hellip;\n","protected":false},"author":2,"featured_media":88811,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":"","_share_on_mastodon":"0"},"categories":[124],"tags":[18218,15523,15524,15513,42916,15528,18220,44979,32532,2082,10873,10874,15525,15515,32534,18219,15517,15518,15519,25671,15521,134,44978,714,10872],"class_list":["post-88810","post","type-post","status-publish","format-standard","has-post-thumbnail","category-roche","tag-amers","tag-ceeu","tag-ch","tag-cmpny","tag-de","tag-destoukbsm","tag-destoushem","tag-drupro","tag-eco","tag-emea","tag-europ","tag-ezc","tag-fin","tag-heca","tag-mce","tag-namer","tag-phar","tag-phar1","tag-phmr","tag-privt","tag-publ","tag-roche","tag-rulesworld-germany","tag-us","tag-weu"],"share_on_mastodon":{"url":"https:\/\/pubeurope.com\/@ch\/116786721293769518","error":""},"_links":{"self":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/88810","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/comments?post=88810"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/posts\/88810\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media\/88811"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/media?parent=88810"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/categories?post=88810"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/ch\/wp-json\/wp\/v2\/tags?post=88810"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}